CD19 and acute lymphoblastic leukemia: CAR T-cell therapy has consistently produced remarkable antitumor activities in hematological system diseases (e.g., cell-derived malignancies) and use of CD19-redirected CAR T cells has generated a complete remission rate of up to 90% in acute lymphoblastic leukemia (ALL) patients7–9.